Recent Updates on Management of Diffuse Large B-Cell Lymphoma
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Treating Newly Diagnosed Patients With DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.
EP. 2: Treatment Considerations in DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.
EP. 3: DLBCL: Approaching CNS Prophylaxis By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health A panel of experts explain how they approach CNS prophylaxis in DLBCL.
EP. 4: Outlook for CNS Lymphoma By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.
EP. 5: Managing Relapsed DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.
EP. 6: Recommendations for Second-Line Therapy in DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.
EP. 7: Data From the L-MIND Trial By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).
EP. 8: DLBCL: Approaches to Treating Patients Ineligible for Transplant By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.
EP. 9: Newer Approvals for Previously Treated DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.
EP. 10: Recommendations for CAR T-Cell Therapy in R/R DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.
EP. 11: Evaluating CAR T Therapies in Lymphoma By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.
EP. 12: Optimal Approaches to Bridging Therapy in DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.
EP. 13: Treating Patients Post CAR T Therapy By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
EP. 14: Looking at the Big Picture in DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.
EP. 15: Exploring Emerging Data in DLBCL By John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
